Gamida Cell Completes Rolling Biologics License Application Submission to the FDA
Gamida Cell (NASDAQ: GMDA), announced positive topline results from its Phase 3 clinical study evaluating the safety and efficacy of omidubicel, an investigational advanced cell therapy in development as a potential life-saving treatment option for patients in need of bone marrow transplant.